Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Ocugen (NASDAQ: OCGN) will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to discuss fourth quarter and full year 2025 financial results and provide a business update.
A pre-market earnings announcement will be issued the same day. Dial-in numbers, conference ID, and a webcast link will be available on the company investor site; a replay and archived webcast will follow.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
OCGN was up 2.13% while peers showed mixed moves (e.g., MBX +3.12%, LRMR -3.81%), indicating a company-specific setup rather than a broad biotech move.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 23 | Earnings call notice | Neutral | +1.3% | Scheduled Q3 2025 call with pre-market earnings release. |
| Jul 17 | Earnings call notice | Neutral | -3.9% | Announced Q2 2025 earnings and business update call timing. |
| May 02 | Earnings call notice | Neutral | +3.6% | Set date for Q1 2025 financial results and update call. |
| Feb 21 | Earnings call notice | Neutral | -2.9% | Planned Q4 and full-year 2024 results and update webcast. |
| Oct 17 | Earnings call notice | Neutral | -1.0% | Announced Q3 2024 earnings call and business update timing. |
Earnings conference-call announcements have produced modest, mixed one-day moves, averaging -0.55% around similar events.
Over the past year, Ocugen has repeatedly scheduled earnings and business update calls at 8:30 a.m. ET with pre‑market releases of results. Prior calls for Q1, Q2, Q3 2025 and full‑year 2024 (e.g., on Nov 5, 2025 and Mar 5, 2025) saw small price reactions, with an average same‑tag move of -0.55%. Today’s notice for Q4 and full‑year 2025 continues this established communications pattern rather than signaling a new strategic shift.
Historical Comparison
In the past year, Ocugen issued 5 similar conferences/earnings call notices with an average one-day move of -0.55%, suggesting historically muted reactions to this type of announcement.
The company has maintained a consistent pattern of pre‑market earnings releases followed by 8:30 a.m. ET calls for quarterly and annual updates across 2024–2025, and this Q4 2025 notice extends that cadence into 2026.
Market Pulse Summary
This announcement schedules Ocugen’s Q4 and full‑year 2025 earnings call for March 4, 2026 at 8:30 a.m. ET, with results to post before the market opens. Historical data show five similar conferences/earnings notices with an average one‑day move of -0.55%, suggesting expectations around such updates have been measured. Investors may later compare the reported figures with recent financings, cash levels, and prior disclosures on losses and funding needs highlighted in recent SEC filings.
AI-generated analysis. Not financial advice.
MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026.
Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:
Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 3029428
Webcast: Available on the events section of the Ocugen investor site
A replay of the call and archived webcast will be available on the Ocugen investor site.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When is Ocugen's (OCGN) conference call for Q4 and full year 2025 results?
How can investors join the Ocugen (OCGN) March 4, 2026 earnings webcast?
What dial-in details does Ocugen (OCGN) provide for the March 4, 2026 call?
Will Ocugen (OCGN) make the March 4, 2026 call available after the live event?
What will Ocugen (OCGN) cover during the March 4, 2026 conference call?
